Safety asssessment of iopromide contrast media: a narrative review focusing on adverse events

1 Chen Z-Y, Wang Y-X, Lin Y, Zhang J-S, Yang F, Zhou Q-L, et al. Advance of molecular imaging technology and targeted imaging agent in imaging and therapy. BioMed Res Int. 2014;2014:819324. Search in Google Scholar

2 Ganguly D, Chakraborty S, Balitanas M, Kin T-H. Medical imaging: A review. In: Security-Enriched Urban Computing and Smart Grid. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. Search in Google Scholar

3 Hussain S, Mubeen J, Ullah N, Shah SS, Khan BA, Zahoor M, et al. Modern diagnostic imaging technique applications and risk factors in the medical field: A review. BioMed Res Int. 2022;2022:5164970. Search in Google Scholar

4 Ros PR, Inan I, Erturk SM. Contrast agents in radiology: An overview, in medical imaging contrast agents. Springer International Publishing; 2021:1-4. Search in Google Scholar

5 Huynh K, Baghdanian AM, Baghdanian AA, Sun DS, Koli KP, Zagoria RJ, et al. Updated guidelines for intravenous contrast use for CT and MRI. Emerg Radiol. 2020;27(2):115-26. Search in Google Scholar

6 Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol. 2009;5(4):403-16. Search in Google Scholar

7 Christiansen C. X-ray contrast media – an overview. Toxicology. 2005;209(2):185-7. Search in Google Scholar

8 Heshmatzadeh Behzadi A, Prince MR. Preventing allergic reactions to gadolinium-based contrast agents. Top Magn Reson Imaging. 2016;25(6):275-9. Search in Google Scholar

9 Koç MM, Aslan N, Kao AP, Barber AH. Evaluation of X-ray tomography contrast agents: A review of production, protocols, and biological applications. Microsc Res Tech. 2019;82(6):812-48. Search in Google Scholar

10 Endrikat J, Michael A, Kolbach R, Lengsfeld P, Vogtlander K. Risk of hypersensitivity reactions to iopromide after intra-arterial versus intravenous administration: A nested case-control analysis of 133,331 patients. Invest Radiol. 2020;55(1):38-44. Search in Google Scholar

11 Cademartiri F, de Monye C, Pugliese F, Mollet NR, Runza G, van der Lugt A, et al. High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: Iopromide 370 versus iomeprol 400. Invest Radiol. 2006;41(3):349-53. Search in Google Scholar

12 Schönmann C, Brockow K. Adverse reactions during procedures: Hypersensitivity to contrast agents and dyes. Ann Allergy Asthma Immunol. 2020;124(2):156-64. Search in Google Scholar

13 Pomara C, Pascale N, Maglietta F, Neri M, Riezzo I, Turillazzi E. Use of contrast media in diagnostic imaging: medico-legal considerations. Radiol Med. 2015;120(9):802-9. Search in Google Scholar

14 Dekker HM, Stroomberg GJ, Prokop M. Tackling the increasing contamination of the water supply by iodinated contrast media. Insights Imaging. 2022;13(1):30. Search in Google Scholar

15 Spampinato MV, Abid A, Matheus MG. Current radiographic iodinated contrast agents. Magn Reson Imaging Clin N Am. 2017;25(4):697-704. Search in Google Scholar

16 Singh J, Daftary A. Iodinated contrast media and their adverse reactions. J Nucl Med Technol. 2008;36(2):69-74. Search in Google Scholar

17 Rosado Ingelmo A, Diaz ID, Moreno RC, Quesado MCM, Garcia-Aviles C, Nunez IG, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol. 2016;26(3):144-55. Search in Google Scholar

18 Lusic H, Grinstaff MW. X-ray-Computed Tomography Contrast Agents. Chem Rev. 2013;113(3):1641-66. Search in Google Scholar

19 Lorusso V, Taroni P, Alvino S, Spinazzi A. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Invest Radiol. 2001;36(6):309-16. Search in Google Scholar

20 Deray G. Dialysis and iodinated contrast media. Kidney Int. 2006;69:25-9. Search in Google Scholar

21 Beckett KR, Moriarity AK, Langer JM. Safe use of contrast media: what the radiologist needs to know. RadioGraphics. 2015;35(6):1738-50. Search in Google Scholar

22 Tramèr MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ. 2006;333(7570):675. Search in Google Scholar

23 Bottinor W, Polkampally P, Jovin I. Adverse reactions to iodinated contrast media. Int J Angiol. 2013;22(03):149-54. Search in Google Scholar

24 Davenport MS, Perazella MA, Yee J, Dillman JR, Fine P, McDonald RJ, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294(3):660-8. Search in Google Scholar

25 Zhang B, Dong Y, Liang L, Lian Z, Liu J, Luo X, et al. The incidence, classification, and management of acute adverse reactions to the low-osmolar iodinated contrast media isovue and ultravist in contrast-enhanced computed tomography scanning. Medicine. 2016;95(12):3170. Search in Google Scholar

26 Gharekhanloo F, Torabian S. Comparison of allergic adverse effects and contrast enhancement between iodixanol and iopromide. Iran J Radiol. 2012;9(2):63-6. Search in Google Scholar

27 An J, Jung H, Kwon OY, Kang Y, Lee JK, Won HK, et al. Differences in adverse reactions among iodinated contrast media: Analysis of the KAERS database. J Allergy Clin Immunol Pract. 2019;7(7):2205-11. Search in Google Scholar

28 Jost G, Pietsch H, Lengsfeld P, Hütter J, Sieber MA. The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol. 2010;45(5):255-61. Search in Google Scholar

29 Goldberg SN, Abrahams J, Drayer BP, Golding S, Bernardino M, Brunetti J. A comparison of iopromide with iopamidol and iohexol for contrast-enhanced computed tomography. Invest Radiol. 1994;29 Suppl 1:S76-83. Search in Google Scholar

30 Jean-Marc I, Emmanuelle P, Philippe P, Claire C. Allergy-like reactions to iodinated contrast agents. A critical analysis. Fundam Clin Pharmacol. 2005;19(3):263-81. Search in Google Scholar

31 Endrikat J, Gerlinger C, Pracz M, Lengsfeld P, Bhatti A, Michel A. Risk of hypersensitivity reactions to iopromide in children and elderly: An analysis of 132,850 patients from 4 observational studies and pharmacovigilance covering >288 million administrations. Invest Radiol. 2022;57(5):318-26. Search in Google Scholar

32 Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11. Search in Google Scholar

33 Mortelé KJ, Oliva M-R, Ondategue S, Ras PR, Silverman SS. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR. 2005; 184(1):31-4. Search in Google Scholar

34 Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three noninterventional studies in 132,012 patients. Acta Radiol. 2014;55(6): 707-14. Search in Google Scholar

35 García M, Aguirre U, Martinez A, Ruiz B, Lertxundi U, Aguirre C. Acute adverse reactions to iopromide vs iomeprol: a retrospective analysis of spontaneous reporting from a radiology department. Br J Radiol. 2014;87(1033):20130511. Search in Google Scholar

36 Juergens CP, Winter JP, Nguyen-Do P, Lo S, French JK, Hallani H, et al. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. Intern Med J. 2009;39(1):25-31. Search in Google Scholar

37 Nie B, Cheng WJ, Li YF, Cao Z, Yang QY, Zhao Y-X, et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv. 2008;72(7):958-65. Search in Google Scholar

38 Dong S-J, Gao X-Y, Pei M-X, Luo T, Fan D, Chen Y-L, et al. Effects and mechanism of salvianolic acid B on the injury of human renal tubular epithelial cells induced by iopromide. Front Pharmacol. 2021;21:761908. Search in Google Scholar

39 Iordache AM, Docea AO, Buga AM, Mitrut R, Albulescu D, Zlatian O, et al. The incidence of skin lesions in contrast media-induced chemical hypersensitivity. Exp Ther Med. 2019;17(2):1113-24. Search in Google Scholar

40 Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: A primer for the non-radiologist. Mayo Clin Proc. 2012;87(4):390-402. Search in Google Scholar

41 Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: an update. Curr Probl Diagn Radiol. 2006;35(4):164-9. Search in Google Scholar

42 Namasivayam S, Kalra MK, Torres WE, Small WC Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol. 2006;12(5):210-5. Search in Google Scholar

43 Matos C, Joaquim J, Pires T. Attitudes and knowledge of community pharmacy professionals regarding the spontaneous reporting of adverse drug reactions: a preliminary study in Coimbra, Portugal. Drugs Ther Perspectiv. 2017;33:88-94. Search in Google Scholar

44 Matos C, Rodrigues L, Joaquim J. Attitudes and opinions of Portuguese community pharmacy professionals towards patient reporting of adverse drug reactions and the pharmacovigilance system. Drug Ther Perspectiv. 2017;33:188-94. Search in Google Scholar

45 Matos C, van Hunsel F, Tavares Ribeiro R, Nascimento do ÓD, Raposo JF. Diabetes patient’s pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation. Ther Adv Drug Saf. 2020;11:2042098620953935. Search in Google Scholar